Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Macroalgal-bacterial interactions: Identification and role of thallusin in morphogenesis of the seaweed Ulva (Chlorophyta).

Alsufyani T, Califano G, Deicke M, Grueneberg J, Weiss A, Engelen AH, Kwantes M, Mohr JF, Ulrich JF, Wichard T.

J Exp Bot. 2020 Feb 4. pii: eraa066. doi: 10.1093/jxb/eraa066. [Epub ahead of print]

PMID:
32016363
2.

Metallophore profiling of nitrogen-fixing Frankia spp. to understand metal management in the rhizosphere of actinorhizal plants.

Deicke M, Mohr JF, Roy S, Herzsprung P, Bellenger JP, Wichard T.

Metallomics. 2019 Apr 17;11(4):810-821. doi: 10.1039/c8mt00344k.

PMID:
30843545
3.

DeltaMS: a tool to track isotopologues in GC- and LC-MS data.

Baumeister TUH, Ueberschaar N, Schmidt-Heck W, Mohr JF, Deicke M, Wichard T, Guthke R, Pohnert G.

Metabolomics. 2018 Feb 27;14(4):41. doi: 10.1007/s11306-018-1336-x.

PMID:
30830340
4.

The cost impact to Medicare of shifting treatment of worsening heart failure from inpatient to outpatient management settings.

Fitch K, Lau J, Engel T, Medicis JJ, Mohr JF, Weintraub WS.

Clinicoecon Outcomes Res. 2018 Dec 14;10:855-863. doi: 10.2147/CEOR.S184048. eCollection 2018.

5.

Iron-organic matter complexes accelerate microbial iron cycling in an iron-rich fen.

Kügler S, Cooper RE, Wegner CE, Mohr JF, Wichard T, Küsel K.

Sci Total Environ. 2019 Jan 1;646:972-988. doi: 10.1016/j.scitotenv.2018.07.258. Epub 2018 Jul 30.

PMID:
30235650
6.

Gramibactin is a bacterial siderophore with a diazeniumdiolate ligand system.

Hermenau R, Ishida K, Gama S, Hoffmann B, Pfeifer-Leeg M, Plass W, Mohr JF, Wichard T, Saluz HP, Hertweck C.

Nat Chem Biol. 2018 Sep;14(9):841-843. doi: 10.1038/s41589-018-0101-9. Epub 2018 Jul 30.

PMID:
30061716
7.

Intravenous fosfomycin for the treatment of hospitalized patients with serious infections.

Shorr AF, Pogue JM, Mohr JF.

Expert Rev Anti Infect Ther. 2017 Oct;15(10):935-945. doi: 10.1080/14787210.2017.1379897. Epub 2017 Sep 22. Review.

PMID:
28901793
8.

The antibiotic pipeline: reviving research and development and speeding drugs to market.

Luepke KH, Mohr JF 3rd.

Expert Rev Anti Infect Ther. 2017 May;15(5):425-433. doi: 10.1080/14787210.2017.1308251. Epub 2017 Mar 29. Review. Erratum in: Expert Rev Anti Infect Ther. 2017 Aug;15(8):805.

PMID:
28306360
9.

Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.

Luepke KH, Suda KJ, Boucher H, Russo RL, Bonney MW, Hunt TD, Mohr JF 3rd.

Pharmacotherapy. 2017 Jan;37(1):71-84. doi: 10.1002/phar.1868. Epub 2016 Dec 27.

PMID:
27859453
10.

Comment on: Efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trials.

Potashman MH, Formella DN, Hamed K, Mohr JF.

J Antimicrob Chemother. 2015 Apr;70(4):1274-5. doi: 10.1093/jac/dku513. Epub 2015 Jan 11. No abstract available.

PMID:
25583745
11.

Metallophore mapping in complex matrices by metal isotope coded profiling of organic ligands.

Deicke M, Mohr JF, Bellenger JP, Wichard T.

Analyst. 2014 Dec 7;139(23):6096-9. doi: 10.1039/c4an01461h. Epub 2014 Oct 9.

PMID:
25298978
12.

Use of daptomycin to treat infections with methicillin-resistant Staphylococcus aureus isolates having vancomycin minimum inhibitory concentrations of 1.5 to 2 μg/mL.

McDaneld PM, Spooner LM, Mohr JF, Belliveau PP.

Ann Pharmacother. 2013 Dec;47(12):1654-65. doi: 10.1177/1060028013508272. Epub 2013 Nov 1. Review.

PMID:
24259618
13.

Significant publications on infectious diseases pharmacotherapy in 2010.

Hirsch EB, Cottreau JM, Ikwuagwu JO, Lusardi K, Mohr JF, Rodriguez SM, Shah DN, Tran TT; Houston Infectious Diseases Network.

Am J Health Syst Pharm. 2011 Nov 1;68(21):2075-85. doi: 10.2146/ajhp110125. Review.

PMID:
22011987
14.

Predictors of relapse of methicillin-resistant Staphylococcus aureus bacteremia after treatment with vancomycin.

Welsh KJ, Skrobarcek KA, Abbott AN, Lewis CT, Kruzel MC, Lewis EM, Gardiner JM, Mohr JF, Armitige LY, Wanger A.

J Clin Microbiol. 2011 Oct;49(10):3669-72. doi: 10.1128/JCM.05287-11. Epub 2011 Aug 24.

15.

Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus.

Kruzel MC, Lewis CT, Welsh KJ, Lewis EM, Dundas NE, Mohr JF, Armitige LY, Wanger A.

J Clin Microbiol. 2011 Jun;49(6):2272-3. doi: 10.1128/JCM.02215-10. Epub 2011 Mar 30.

16.

Prospective survey of (1→3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting.

Mohr JF, Sims C, Paetznick V, Rodriguez J, Finkelman MA, Rex JH, Ostrosky-Zeichner L.

J Clin Microbiol. 2011 Jan;49(1):58-61. doi: 10.1128/JCM.01240-10. Epub 2010 Nov 3.

17.

Decreasing the probability of creatine phosphokinase elevations: clinical considerations for daptomycin dosing in obese patients.

Donovan BJ, Mohr JF, Knapp AG, Eisenstein BI.

Clin Infect Dis. 2010 Oct 15;51(8):989; author reply 989-90. doi: 10.1086/656440. No abstract available.

PMID:
20858080
18.

Influenza vaccination rates among pharmacists.

Ruiz AD, Frei CR, Barner JC, Carson JJ, Oramasionwu CU, Ruiz JL, Daniels KR, Mohr JF, Klepser ME.

J Am Pharm Assoc (2003). 2010 Jul-Aug;50(4):517-22. doi: 10.1331/JAPhA.2010.09146.

PMID:
20621870
19.

Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin.

Welsh KJ, Abbott AN, Lewis EM, Gardiner JM, Kruzel MC, Lewis CT, Mohr JF, Wanger A, Armitige LY.

J Clin Microbiol. 2010 Mar;48(3):894-9. doi: 10.1128/JCM.01949-09. Epub 2010 Jan 20.

20.

Antimicrobial susceptibility testing: a primer for clinicians.

Kuper KM, Boles DM, Mohr JF, Wanger A.

Pharmacotherapy. 2009 Nov;29(11):1326-43. doi: 10.1592/phco.29.11.1326. Review.

PMID:
19857149
21.

Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies.

Steenbergen JN, Mohr JF, Thorne GM.

J Antimicrob Chemother. 2009 Dec;64(6):1130-8. doi: 10.1093/jac/dkp346. Epub 2009 Oct 12. Review.

PMID:
19825818
22.

Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).

Mohr JF, Friedrich LV, Yankelev S, Lamp KC.

Int J Antimicrob Agents. 2009 Jun;33(6):543-8. doi: 10.1016/j.ijantimicag.2008.12.007. Epub 2009 Feb 6.

PMID:
19201165
23.

Significant publications on infectious diseases pharmacotherapy in 2007.

Yeh RF, Kuper KM, Coyle EA, Garey KW, Ikwuagwu JO, Maclayton DO, Mohr JF, Musick WL, Pass SE, Rios E, Tam VH; Houston Infectious Disease Network.

Am J Health Syst Pharm. 2008 Nov 15;65(22):e72-9. doi: 10.2146/ajhp080182.

PMID:
18997127
24.

Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections.

Mohr JF 3rd.

Clin Infect Dis. 2008 Sep 15;47 Suppl 1:S41-51. doi: 10.1086/590065. Review.

PMID:
18713049
25.

Dysglycaemias and fluoroquinolones.

Lewis RJ, Mohr JF 3rd.

Drug Saf. 2008;31(4):283-92. Review.

PMID:
18366239
26.

Risk factors for hyperglycemia in hospitalized adults receiving gatifloxacin: a retrospective, nested case-controlled analysis.

Mohr JF 3rd, Peymann PJ, Troxell E, Lodise TP, Ostrosky-Zeichner L.

Clin Ther. 2008 Jan;30(1):152-7. doi: 10.1016/j.clinthera.2008.01.009.

PMID:
18343251
27.

Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury.

Mohr JF 3rd, Ostrosky-Zeichner L, Wainright DJ, Parks DH, Hollenbeck TC, Ericsson CD.

Antimicrob Agents Chemother. 2008 May;52(5):1891-3. doi: 10.1128/AAC.01321-07. Epub 2008 Feb 25.

28.

Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients.

Lodise T, Graves J, Miller C, Mohr JF, Lomaestro B, Smith RP.

Pharmacotherapy. 2007 Nov;27(11):1498-505.

PMID:
17963459
29.

Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus.

Mohr JF, Murray BE.

Clin Infect Dis. 2007 Jun 15;44(12):1536-42. Epub 2007 May 4.

PMID:
17516395
30.

A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone.

Mohr JF, McKinnon PS, Peymann PJ, Kenton I, Septimus E, Okhuysen PC.

Pharmacotherapy. 2005 Oct;25(10):1303-9.

PMID:
16185173
31.

Fatal amphotericin B overdose due to administration of nonlipid formulation instead of lipid formulation.

Mohr JF, Hall AC, Ericsson CD, Ostrosky-Zeichner L.

Pharmacotherapy. 2005 Mar;25(3):426-8.

PMID:
15843289
32.
33.

Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients.

Mohr JF, Finkel KW, Rex JH, Rodriguez JR, Leitz GJ, Ostrosky-Zeichner L.

Antimicrob Agents Chemother. 2004 Aug;48(8):3151-3.

34.
35.

Use of systemically administered penicillin as a prophylactic against ophthalmia neonatorum.

SWEET LK, BARTER RH, COMMINGS P, FEATHERSTONE WM, PARKER GF, OVEN R, FAIRCHILD JP, MOHR JF, McDONALD JJ, MILLER RT.

AMA Am J Dis Child. 1950 Nov;80(5):868-71. No abstract available.

PMID:
14777171

Supplemental Content

Support Center